Literature DB >> 30185549

CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases.

Jiaxin Liang1, Mengqian Chen1, Daniel Hughes2, Alexander A Chumanevich1, Serena Altilia1, Vimala Kaza1, Chang-Uk Lim1, Hippokratis Kiaris1, Karthikeyan Mythreye3, Maria Marjorette Pena2, Eugenia V Broude1, Igor B Roninson4.   

Abstract

: Unresectable hepatic metastases of colon cancer respond poorly to existing therapies and are a major cause of colon cancer lethality. In this study, we evaluated the therapeutic viability of targeting the mediator kinase CDK8, an early clinical stage drug target, as a means to suppress metastasis of colon cancer. CDK8 was amplified or overexpressed in many colon cancers and CDK8 expression correlated with shorter patient survival. Knockdown or inhibition of CDK8 had little effect on colon cancer cell growth but suppressed metastatic growth of mouse and human colon cancer cells in the liver. This effect was due in part to inhibition of already established hepatic metastases, indicating therapeutic potential of CDK8 inhibitors in the metastatic setting. In contrast, knockdown or inhibition of CDK8 had no significant effect on the growth of tumors implanted subcutaneously, intrasplenically, or orthotopically in the cecum. CDK8 mediated colon cancer growth in the liver through downregulation of matrix metalloproteinase (MMP) inhibitor TIMP3 via TGFβ/SMAD-driven expression of a TIMP3-targeting microRNA, miR-181b, along with induction of Mmp3 in murine or MMP9 in human colon cancer cells via Wnt/β-catenin-driven transcription. These findings reveal a new mechanism for negative regulation of gene expression by CDK8 and a site-specific role for CDK8 in colon cancer hepatic metastasis. Our results indicate the utility of CDK8 inhibitors for the treatment of colon cancer metastases in the liver and suggest that CDK8 inhibitors may be considered in other therapeutic settings involving TGFβ/SMAD or Wnt/β-catenin pathway activation. SIGNIFICANCE: These findings demonstrate that inhibition of the transcription-regulating kinase CDK8 exerts a site-specific tumor-suppressive effect on colon cancer growth in the liver, representing a unique therapeutic opportunity for the treatment of advanced colon cancer.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/23/6594/F1.large.jpg. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30185549      PMCID: PMC6279600          DOI: 10.1158/0008-5472.CAN-18-1583

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer.

Authors:  Eugenia V Broude; Balázs Győrffy; Alexander A Chumanevich; Mengqian Chen; Martina S J McDermott; Michael Shtutman; James F Catroppo; Igor B Roninson
Journal:  Curr Cancer Drug Targets       Date:  2015       Impact factor: 3.428

2.  Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells.

Authors:  Liv Johannessen; Thomas B Sundberg; Daniel J O'Connell; Raivo Kolde; James Berstler; Katelyn J Billings; Bernard Khor; Brinton Seashore-Ludlow; Anne Fassl; Caitlin N Russell; Isabel J Latorre; Baishan Jiang; Daniel B Graham; Jose R Perez; Piotr Sicinski; Andrew J Phillips; Stuart L Schreiber; Nathanael S Gray; Alykhan F Shamji; Ramnik J Xavier
Journal:  Nat Chem Biol       Date:  2017-08-14       Impact factor: 15.040

Review 3.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

4.  Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1.

Authors:  Xiaoping Zhao; Daorong Feng; Qun Wang; Arian Abdulla; Xiao-Jun Xie; Jie Zhou; Yan Sun; Ellen S Yang; Lu-Ping Liu; Bhavapriya Vaitheesvaran; Lauren Bridges; Irwin J Kurland; Randy Strich; Jian-Quan Ni; Chenguang Wang; Johan Ericsson; Jeffrey E Pessin; Jun-Yuan Ji; Fajun Yang
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

Review 5.  The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.

Authors:  Robert S Kerbel; Yuval Shaked
Journal:  Cancer Lett       Date:  2017-02-12       Impact factor: 8.679

6.  Downregulation of CDK-8 inhibits colon cancer hepatic metastasis by regulating Wnt/β-catenin pathway.

Authors:  Wen-Song Cai; Fei Shen; Zhe Feng; Ji-Wei Chen; Qi-Cai Liu; Er-Mao Li; Bo Xu; Jie Cao
Journal:  Biomed Pharmacother       Date:  2015-08-15       Impact factor: 6.529

7.  The Angiogenic Effect of microRNA-21 Targeting TIMP3 through the Regulation of MMP2 and MMP9.

Authors:  Jianzhong Hu; Shuangfei Ni; Yong Cao; Tao Zhang; Tianding Wu; Xianzhen Yin; Ye Lang; Hongbin Lu
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

8.  Copy number profiles of paired primary and metastatic colorectal cancers.

Authors:  Futoshi Kawamata; Ann-Marie Patch; Katia Nones; Catherine Bond; Diane McKeone; Sally-Ann Pearson; Shigenori Homma; Cheng Liu; Lochlan Fennell; Troy Dumenil; Gunter Hartel; Nozomi Kobayasi; Hideki Yokoo; Moto Fukai; Hiroshi Nishihara; Toshiya Kamiyama; Matthew E Burge; Christos S Karapetis; Akinobu Taketomi; Barbara Leggett; Nicola Waddell; Vicki Whitehall
Journal:  Oncotarget       Date:  2017-12-15

9.  Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.

Authors:  Martina S J McDermott; Alexander A Chumanevich; Chang-Uk Lim; Jiaxin Liang; Mengqian Chen; Serena Altilia; David Oliver; James M Rae; Michael Shtutman; Hippokratis Kiaris; Balázs Győrffy; Igor B Roninson; Eugenia V Broude
Journal:  Oncotarget       Date:  2017-02-21

Review 10.  The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications.

Authors:  Gert G Van den Eynden; Ali W Majeed; Martin Illemann; Peter B Vermeulen; Nigel C Bird; Gunilla Høyer-Hansen; Rikke Løvendahl Eefsen; Andrew R Reynolds; Pnina Brodt
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

View more
  21 in total

Review 1.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

2.  Genome Editing As an Approach to the Study of in Vivo Transcription Reprogramming.

Authors:  Y Y Silaeva; V A Kalmykov; E A Varlamova; E N Korshunov; D S Korshunova; M V Kubekina; A A Shtil; I B Roninson; A V Deykin
Journal:  Dokl Biochem Biophys       Date:  2020-04-27       Impact factor: 0.788

3.  CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients.

Authors:  Dan Wang; Yanhong Zhou; Li Hua; Jiaxiang Li; Ni Zhu; Yifei Liu
Journal:  Int J Gen Med       Date:  2022-02-27

4.  Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.

Authors:  Xiaokai Ding; Amanda C Sharko; Martina S J McDermott; Gary P Schools; Alexander Chumanevich; Hao Ji; Jing Li; Li Zhang; Zachary T Mack; Vitali Sikirzhytski; Michael Shtutman; Laura Ivers; Norma O'Donovan; John Crown; Balázs Győrffy; Mengqian Chen; Igor B Roninson; Eugenia V Broude
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

5.  Differential cofactor dependencies define distinct types of human enhancers.

Authors:  Christoph Neumayr; Vanja Haberle; Leonid Serebreni; Katharina Karner; Oliver Hendy; Ann Boija; Jonathan E Henninger; Charles H Li; Karel Stejskal; Gen Lin; Katharina Bergauer; Michaela Pagani; Martina Rath; Karl Mechtler; Cosmas D Arnold; Alexander Stark
Journal:  Nature       Date:  2022-06-01       Impact factor: 69.504

6.  Long non-coding RNA RPSAP52 upregulates Timp3 by serving as the endogenous sponge of microRNA-365 in diabetic retinopathy.

Authors:  Tongtong Niu; Yan An; Tingting Lv; Dongning Liu
Journal:  Exp Ther Med       Date:  2020-10-22       Impact factor: 2.447

7.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

8.  LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.

Authors:  Hong Zhang; Yao-Zhen Pan; May Cheung; Mary Cao; Chao Yu; Ling Chen; Lei Zhan; Zhi-Wei He; Cheng-Yi Sun
Journal:  Cell Death Dis       Date:  2019-03-08       Impact factor: 8.469

Review 9.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

10.  Identifying Cancers Impacted by CDK8/19.

Authors:  Igor B Roninson; Balázs Győrffy; Zachary T Mack; Alexander A Shtil; Michael S Shtutman; Mengqian Chen; Eugenia V Broude
Journal:  Cells       Date:  2019-08-03       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.